At a glance
- Originator N-Gene Research Laboratories
- Developer Allos Therapeutics; Mitochon Technologies; N-Gene Research Laboratories; Sinusventure; University of Melbourne
- Class Antihyperglycaemics; Oximes; Piperidines; Small molecules
- Mechanism of Action HSP70 heat shock protein stimulants; JNK mitogen-activated protein kinase inhibitors; Oxygen radical formation antagonists; Poly(ADP-ribose) polymerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Duchenne muscular dystrophy
Highest Development Phases
- Phase II/III COVID 2019 infections
- Phase II Insulin resistance; Sinus tachycardia
- No development reported Duchenne muscular dystrophy; Inborn genetic disorders
- Discontinued Chemotherapy-induced damage; Reperfusion injury; Type 2 diabetes mellitus
Most Recent Events
- 28 Nov 2023 No recent reports of development identified for phase-I development in COVID-2019-infections in USA (PO, Capsule)
- 28 Nov 2023 No recent reports of development identified for phase-I development in Inborn genetic disorders in USA (PO, Capsule)
- 28 Nov 2023 No recent reports of development identified for phase-I development in Sinus-tachycardia in USA (PO, Capsule)